"Ik heb uitgezaaide longkanker, zo goed als ongeneesbaar. Ik heb verschillende keren geprobeerd om te stoppen met roken, maar het lukt me niet." Waarom is het zo moeilijk om te stoppen met roken? Bekijk hier de #terzaketv reportage van stein falk: vrtnws.be/p.RqkPvZbXRp6

Thanks for sharing, hope you like the figures! Laure-Anne Teuwen

"Nergens zijn automobilisten zo agressief als in België." Zeno (32) doorkruiste bijna heel Europa met de fiets: “Ik kan eerlijk zeggen: in België hebben we een probleem” hln.be/binnenland/zen…

A reminder that Elsevier made $10.5 BILLION in 2022 from selling your academic journals and articles behind paywalls, and make more profit than Amazon, Google, and Apple every year… And paid the academics who wrote the articles $0 And paid the reviewers of the articles $0

🚨#OncologyNursing podcast🚨 'Management of Skin Toxicity with Multikinase Inhibitors' Listen to Beth Wittmer #RN & Hans Prenen from GI CONNECT discuss this topic in this 20-min #MedEd podcast 👉ow.ly/YlL350Omp6e #CRCSM #CRC #Nurse

Late breaking at #ASCO23: In the PROSPECT trial comparing preoperative chemoradiotherapy and FOLFOX in patients with rectal cancer undergoing sphincter-sparing surgery, 5-year disease-free survival was 80.8% with FOLFOX and 78.6% with chemoradiotherapy. nej.md/3WMEmkS

The accompanying paper in Journal of Clinical Oncology is very important, as both regimens have distinct toxicity profiles. Patient-Reported Outcomes (PROs) During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048) ascopubs.org/doi/full/10.12… #ASCO23

🚨🚨🚨 PROSPECT Trial has landed! Congratulations to all investigators, Alliance for Clinical Trials in Oncology, for this important trial! This study is important, will shape, and SHOULD alter practice for OPERATIVELY managed patients with favorable risk LA- rectal cancer. nejm.org/doi/full/10.10…

To select the most notable data from the oral abstract session on #GIcancer @ #ASCO23 MediMix sought the expertise of Prof. Dr Hans Prenen Hans Prenen, a digestive oncologist at UZA ➡️ Video at bit.ly/3oOsNwU

Thanks Willem Lybaert for taking pictures on all important oncology meetings :)

Have not read the paper yet, but am sure the RadOncs will react soon (as they did with Prospect in rectal) :)

🔥 Live vanuit Madrid met dagelijkse #ESMO2023 updates! 🇪🇸 Volg ons en blokkeer alvast 8/11 voor onze exclusieve Post-ESMO avond. Dé kans om dieper in de hoogtepunten te duiken en te netwerken. 👉medimix.be/post-esmo-2023… #MediMix #PostESMO2023 #ESMO2023 #oncologie #Oncology

MTAP loss in #BiliaryCancer in up to 20% of patients. Matched treatment study currently ongoing at our institution UZA (PI Hans Prenen) #ESMO2023

A panel of GI oncologists discuss the emerging data likely to impact clinical practice Watch the recorded discussion here 👉cor2ed.com/gi-connect/pro… Organised in partnership with eChinaHealth and GI CONNECT members Dominik Paul Modest Hans Prenen #MedEd

Another great submission for the Belgian Society of Medical Oncology #bsmoxmas Jumper Xmas Campaign by the oncology team from UZA Hans Prenen Timon Vandamme Laure-Anne Teuwen Annelies Verbiest #SevilayAltintas and others 🇧🇪 ⭐️🧑‍🎄🎄📸 StichtingtegenKanker

Alright! It’s that time of the year again. #ASCO24 is about to start. Here are our now classic rules of engagement. (Still don’t know the author to quote and credit). As usual Steven Vogl is exempt. @asco @oncoalert Nathan A. Pennell MD, PhD, FASCO Narjust Florez, MD, FASCO Dr. Estela Rodriguez Stephanie Graff, MD, FACP, FASCO Dr Sunil Verma Mike Thompson, MD, PhD, FASCO

If you are working in the field of GI Cancers and Global Oncology, we invite you to submit to the Article Collection "Treating GI cancers in resource-restricted countries" in Gastrointestinal Oncology: Management and Care. invt.io/1txbhft5wz9 Hans Prenen AORTIC

Who made this? 😂

Hoewel het voor darmkanker slechts in beperkt aantal gevallen (< 10%) werkt is #immuuntherapie toch zeer grote doorbraak in behandeling kanker! 🍀💪🏻 Prof Hans Prenen diensthoofd oncologie UZA UAntwerpen legt alles mooi uit in HLN.BE 😉 Stop Darmkanker 💙 #kennisdelen

Are you excited for #ESMO24 and the emerging data in GI oncology? Lower GI experts, Chiara Cremolini and Hans Prenen, will be covering the most hotly anticipated data, including the POD1UM-303 study Watch this space for more over the coming weeks!